Main products
Generic and biological innovator products for global markets.
JuvenAspiration supports a focused portfolio spanning anticoagulants, cardiovascular medicines, and novel biologics, with NMPA approval and international registration pathways across US FDA, EMA, and EU markets.
Generic
Rivaroxaban
Reference product: Xarelto. Strength: 10mg, 15mg, 20mg. Regulatory status: NMPA approval, US FDA approval, EMA approval.
Generic
Apixaban
Reference product: Eliquis. Strength: 2.0mg, 5.0mg. Regulatory status: NMPA approval, US FDA approval, EMA approval.
Generic
Rosuvastatin
Reference product: Crestor. Strength: 5mg, 10mg, 20mg, 40mg. Regulatory status: NMPA approval, US FDA approval, EMA approval.
Generic
Ticagrelor
Reference product: Brilinta/Brilique. Strength: 60mg, 90mg. Regulatory status: NMPA approval, US FDA approval, EMA approval.
Biological innovator
Siltartoxatug Injection
Next-generation passive immunity for tetanus prevention. IgG1 recombinant fully native human monoclonal antibody against tetanus toxin.
Biological innovator
Retavibart Injection
Long-acting anti-RSV monoclonal antibody for infant protection, referencing nirsevimab and clesrovimab development pathways.
Product details, regulatory status, and partnership materials are available for qualified pharmaceutical and distribution partners.
JuvenAspiration Biotech
Improving lives through connecting China Pharmaceutical to global patients.
About · Products · Contact